A Phase 1 interventional study of ABBV-932 and Placebo for ABBV-932 in Healthy Volunteers, Generalized Anxiety Disorder (GAD) and Bipolar Disorder (BPD), sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 133rd largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 10 in phase 1, and was the 219th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 8 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For healthy volunteer cohort:
-- (BMI) is >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.
For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ABBV-932 once daily (QD) for 14 days.
Drug: ABBV-932
Participants will receive placebo for ABBV-932 QD for 14 days.
Drug: Placebo for ABBV-932
Participants will receive ABBV-932 QD for 28 days.
Drug: ABBV-932
Participants will receive placebo for ABBV-932 QD for 28 days.
Drug: Placebo for ABBV-932
Participants will receive ABBV-932 QD for 28 days.
Drug: ABBV-932
Participants will receive placebo for ABBV-932 QD for 28 days.
Drug: Placebo for ABBV-932
Participants will receive ABBV-932 QD for 42 days.
Drug: ABBV-932
Participants will receive placebo for ABBV-932 QD for 42 days.
Drug: Placebo for ABBV-932
Capsule; oral
Capsule; oral
Maximum Observed Plasma Concentration (Cmax)
Cmax will be assessed.
Time frame: Up to Day 28
Time to Cmax (Tmax)
Tmax will be assessed.
Time frame: Up to Day 28
Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)
Ctrough will be assessed.
Time frame: Up to Day 28
Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)
AUCtau will be assessed.
Time frame: Up to Day 28
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Baseline to Day 129
Plan to share: No
Ran from Aug 2023 to primary completion in Mar 2025, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-932
Generalized Anxiety Disorder →